About
Technology
Issues
FAQ
Links
Official Page
SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.